Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Isocitrate Dehydrogenase"" wg kryterium: Temat


Tytuł :
Safety and efficacy of BAY1436032 in IDH1-mutant AML: phase I study results.
Autorzy :
Heuser M; Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany. .
Palmisiano N; Department of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA.
Mantzaris I; Department of Medical Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA.
Mims A; Division of Hematology, Department of Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
DiNardo C; Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
Silverman LR; Tisch Cancer Institute, Division of Hematology/Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Wang ES; Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
Fiedler W; Department of Hematology and Oncology, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
Baldus C; Division of Hematology and Oncology, Charité University Hospital Berlin, Berlin, Germany.
Schwind S; Division of Hematology and Oncology, University Hospital Leipzig, Leipzig, Germany.
Pardee T; Section on Hematology and Oncology, Comprehensive Cancer Center of Wake Forest Baptist Health, Winston-Salem, NC, USA.
Perl AE; Division of Hematology-Oncology, Perelman School of Medicine, Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA, USA.
Cai C; Pharmaceuticals Division, Bayer HealthCare Pharmaceuticals, Inc., Whippany, NJ, USA.
Kaulfuss S; Pharmaceuticals Division, Bayer AG, Berlin, Germany.
Lagkadinou E; Pharmaceuticals Division, Bayer AG, Berlin, Germany.
Rentzsch C; Pharmaceuticals Division, Bayer AG, Berlin, Germany.
Wagner M; Pharmaceuticals Division, Bayer AG, Berlin, Germany.
Wilkinson G; Pharmaceuticals Division, Bayer AG, Berlin, Germany.
Wu B; Pharmaceuticals Division, Bayer HealthCare Pharmaceuticals, Inc., Whippany, NJ, USA.
Jeffers M; Pharmaceuticals Division, Bayer HealthCare Pharmaceuticals, Inc., Whippany, NJ, USA.
Genvresse I; Pharmaceuticals Division, Bayer AG, Berlin, Germany.
Krämer A; Clinical Cooperation Unit Molecular Hematology/Oncology, German Cancer Research Center (DKFZ) and Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany.
Pokaż więcej
Źródło :
Leukemia [Leukemia] 2020 Nov; Vol. 34 (11), pp. 2903-2913. Date of Electronic Publication: 2020 Jul 30.
Typ publikacji :
Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms :
Molecular Targeted Therapy*
Mutation*
Aniline Compounds/*therapeutic use
Antineoplastic Agents/*therapeutic use
Benzimidazoles/*therapeutic use
Enzyme Inhibitors/*therapeutic use
Isocitrate Dehydrogenase/*antagonists & inhibitors
Isocitrate Dehydrogenase/*genetics
Leukemia, Myeloid, Acute/*drug therapy
Leukemia, Myeloid, Acute/*genetics
Adult ; Aged ; Aniline Compounds/administration & dosage ; Aniline Compounds/adverse effects ; Aniline Compounds/pharmacokinetics ; Antineoplastic Agents/administration & dosage ; Antineoplastic Agents/adverse effects ; Antineoplastic Agents/pharmacokinetics ; Benzimidazoles/administration & dosage ; Benzimidazoles/adverse effects ; Benzimidazoles/pharmacokinetics ; Bone Marrow/pathology ; DNA Mutational Analysis ; Enzyme Inhibitors/administration & dosage ; Enzyme Inhibitors/adverse effects ; Enzyme Inhibitors/pharmacokinetics ; Female ; Humans ; Isocitrate Dehydrogenase/metabolism ; Leukemia, Myeloid, Acute/diagnosis ; Leukemia, Myeloid, Acute/mortality ; Male ; Middle Aged ; Prognosis ; Survival Analysis ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Evaluating ivosidenib for the treatment of acute myeloid leukemia.
Autorzy :
Donker ML; Department of Haematology, Amsterdam UMC, Vrije Universiteit University Medical Center , Amsterdam, The Netherlands.
Ossenkoppele GJ; Department of Haematology, Amsterdam UMC, Vrije Universiteit University Medical Center , Amsterdam, The Netherlands.
Pokaż więcej
Źródło :
Expert opinion on pharmacotherapy [Expert Opin Pharmacother] 2020 Dec; Vol. 21 (18), pp. 2205-2213. Date of Electronic Publication: 2020 Aug 18.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Antineoplastic Agents/*therapeutic use
Glycine/*analogs & derivatives
Isocitrate Dehydrogenase/*antagonists & inhibitors
Leukemia, Myeloid, Acute/*drug therapy
Pyridines/*therapeutic use
Adult ; Antineoplastic Agents/administration & dosage ; Antineoplastic Agents/adverse effects ; Antineoplastic Agents/blood ; Clinical Trials as Topic ; Dose-Response Relationship, Drug ; Glycine/administration & dosage ; Glycine/adverse effects ; Glycine/blood ; Glycine/therapeutic use ; Humans ; Isocitrate Dehydrogenase/genetics ; Leukemia, Myeloid, Acute/enzymology ; Mutation ; Pyridines/administration & dosage ; Pyridines/adverse effects ; Pyridines/blood ; Treatment Outcome
Czasopismo naukowe
Tytuł :
All-Trans Retinoic Acid Synergizes with Enasidenib to Induce Differentiation of IDH2-Mutant Acute Myeloid Leukemia Cells.
Autorzy :
Kim Y; Department of Internal Medicine, Yonsei Wonju College of Medicine, Wonju, Korea.
Jeung HK; Avison Biomedical Research Center, Yonsei University College of Medicine, Seoul, Korea.
Cheong JW; Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
Song J; Department of Laboratory Medicine, Yonsei University College of Medicine, Seoul, Korea.
Bae SH; Severance Biomedical Science Institute, Yonsei Biomedical Research Institute, Yonsei University College of Medicine, Seoul, Korea.
Lee JI; Department of Internal Medicine, Yonsei Wonju College of Medicine, Wonju, Korea.
Min YH; Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea. .
Pokaż więcej
Źródło :
Yonsei medical journal [Yonsei Med J] 2020 Sep; Vol. 61 (9), pp. 762-773.
Typ publikacji :
Journal Article
MeSH Terms :
Aminopyridines/*pharmacology
Antineoplastic Agents/*pharmacology
Cell Differentiation/*drug effects
Drug Resistance, Neoplasm/*drug effects
Enzyme Inhibitors/*pharmacology
Isocitrate Dehydrogenase/*genetics
Leukemia, Myeloid, Acute/*drug therapy
Tretinoin/*pharmacology
Triazines/*pharmacology
Drug Resistance, Neoplasm/genetics ; Humans ; Isocitrate Dehydrogenase/antagonists & inhibitors ; Isocitrate Dehydrogenase/metabolism ; Leukemia, Myeloid, Acute/genetics ; Mutation
Czasopismo naukowe
Tytuł :
Discovery of a Novel Chemical Scaffold Against Mutant Isocitrate Dehydrogenase 1 (IDH1).
Autorzy :
Kang CH; Therapeutics & Biotechnology Division, Korea Research Institute of Chemical Technology, Daejeon, Republic of Korea.; College of Pharmacy, Chungnam National University, Daejeon, Republic of Korea.
Choi SU; Therapeutics & Biotechnology Division, Korea Research Institute of Chemical Technology, Daejeon, Republic of Korea.
Son YH; Therapeutics & Biotechnology Division, Korea Research Institute of Chemical Technology, Daejeon, Republic of Korea.
Lee HK; Therapeutics & Biotechnology Division, Korea Research Institute of Chemical Technology, Daejeon, Republic of Korea.
Jeong HG; College of Pharmacy, Chungnam National University, Daejeon, Republic of Korea.
Yun CS; Therapeutics & Biotechnology Division, Korea Research Institute of Chemical Technology, Daejeon, Republic of Korea.; Medicinal Chemistry and Pharmacology, Korea University of Science and Technology, Daejeon, Republic of Korea.
Ahn S; Therapeutics & Biotechnology Division, Korea Research Institute of Chemical Technology, Daejeon, Republic of Korea .
Park CH; Therapeutics & Biotechnology Division, Korea Research Institute of Chemical Technology, Daejeon, Republic of Korea .; Medicinal Chemistry and Pharmacology, Korea University of Science and Technology, Daejeon, Republic of Korea.
Pokaż więcej
Źródło :
Anticancer research [Anticancer Res] 2020 Sep; Vol. 40 (9), pp. 4929-4935.
Typ publikacji :
Journal Article
MeSH Terms :
Antineoplastic Agents/*pharmacology
Isocitrate Dehydrogenase/*antagonists & inhibitors
Isocitrate Dehydrogenase/*genetics
Antineoplastic Agents/chemistry ; Cell Line, Tumor ; Drug Discovery ; Glutarates/metabolism ; Humans ; Isocitrate Dehydrogenase/metabolism ; Molecular Structure ; Mutation ; Small Molecule Libraries/chemistry ; Small Molecule Libraries/pharmacology
Czasopismo naukowe
Tytuł :
Enasidenib and ivosidenib in AML.
Autorzy :
Martelli MP; Section of Hematology and Clinical Immunology, Department of Medicine, University of Perugia, Perugia, Italy - .
Martino G; Section of Hematology and Clinical Immunology, Department of Medicine, University of Perugia, Perugia, Italy.
Cardinali V; Section of Hematology and Clinical Immunology, Department of Medicine, University of Perugia, Perugia, Italy.
Falini B; Section of Hematology and Clinical Immunology, Department of Medicine, University of Perugia, Perugia, Italy.
Martinelli G; IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola, Forlì-Cesena, Italy.
Cerchione C; Unit of Hematology, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola, Forlì-Cesena, Italy.
Pokaż więcej
Źródło :
Minerva medica [Minerva Med] 2020 Oct; Vol. 111 (5), pp. 411-426. Date of Electronic Publication: 2020 Sep 21.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Aminopyridines/*therapeutic use
Antineoplastic Agents/*therapeutic use
Glycine/*analogs & derivatives
Isocitrate Dehydrogenase/*antagonists & inhibitors
Leukemia, Myeloid, Acute/*drug therapy
Pyridines/*therapeutic use
Triazines/*therapeutic use
Aminopyridines/adverse effects ; Antineoplastic Agents/adverse effects ; Cell Differentiation/drug effects ; Clinical Trials as Topic ; Glutarates/metabolism ; Glycine/adverse effects ; Glycine/therapeutic use ; Humans ; Isocitrate Dehydrogenase/genetics ; Isocitrate Dehydrogenase/metabolism ; Isocitrates/metabolism ; Ketoglutaric Acids/metabolism ; Leukemia, Myeloid, Acute/genetics ; Leukemia, Myeloid, Acute/metabolism ; Leukemia, Myeloid, Acute/pathology ; Multicenter Studies as Topic ; Mutation, Missense ; NADP/biosynthesis ; Pyridines/adverse effects ; Syndrome ; Triazines/adverse effects
Czasopismo naukowe
Tytuł :
Diagnostic accuracy and potential covariates for machine learning to identify IDH mutations in glioma patients: evidence from a meta-analysis.
Autorzy :
Zhao J; Department of Radiology, The First Affiliated Hospital, Sun Yat-Sen University, 58, The Second Zhongshan Road, Guangzhou, 510080, Guangdong, China.
Huang Y; Department of Radiology, The First Affiliated Hospital, Sun Yat-Sen University, 58, The Second Zhongshan Road, Guangzhou, 510080, Guangdong, China.
Song Y; Department of Radiology, The First Affiliated Hospital of Xiamen University, Xiamen, 361003, China.
Xie D; Department of Radiology, The First Affiliated Hospital, Sun Yat-Sen University, 58, The Second Zhongshan Road, Guangzhou, 510080, Guangdong, China.
Hu M; Department of Radiology, The First Affiliated Hospital, Sun Yat-Sen University, 58, The Second Zhongshan Road, Guangzhou, 510080, Guangdong, China.
Qiu H; Department of Radiology, The First Affiliated Hospital, Sun Yat-Sen University, 58, The Second Zhongshan Road, Guangzhou, 510080, Guangdong, China.
Chu J; Department of Radiology, The First Affiliated Hospital, Sun Yat-Sen University, 58, The Second Zhongshan Road, Guangzhou, 510080, Guangdong, China. .
Pokaż więcej
Źródło :
European radiology [Eur Radiol] 2020 Aug; Vol. 30 (8), pp. 4664-4674. Date of Electronic Publication: 2020 Mar 19.
Typ publikacji :
Journal Article; Meta-Analysis; Review
MeSH Terms :
Machine Learning*
Mutation*
Brain Neoplasms/*diagnosis
DNA, Neoplasm/*genetics
Glioma/*diagnosis
Isocitrate Dehydrogenase/*genetics
Magnetic Resonance Imaging/*methods
Biomarkers, Tumor/genetics ; Biomarkers, Tumor/metabolism ; Brain Neoplasms/genetics ; DNA Mutational Analysis ; Glioma/genetics ; Humans ; Isocitrate Dehydrogenase/metabolism ; ROC Curve
Czasopismo naukowe
Tytuł :
Isocitrate dehydrogenase 1 mutation enhances 24(S)-hydroxycholesterol production and alters cholesterol homeostasis in glioma.
Autorzy :
Yang R; State Key Laboratory of Cancer Biology, Department of Pathology, Xijing Hospital and School of Basic Medicine, Fourth Military Medical University, 710032, Xi'an, Shaanxi, China.
Zhao Y; State Key Laboratory of Cancer Biology, Department of Pathology, Xijing Hospital and School of Basic Medicine, Fourth Military Medical University, 710032, Xi'an, Shaanxi, China.
Gu Y; State Key Laboratory of Cancer Biology, Department of Pathology, Xijing Hospital and School of Basic Medicine, Fourth Military Medical University, 710032, Xi'an, Shaanxi, China.
Yang Y; State Key Laboratory of Cancer Biology, Department of Pathology, Xijing Hospital and School of Basic Medicine, Fourth Military Medical University, 710032, Xi'an, Shaanxi, China.
Gao X; State Key Laboratory of Cancer Biology, Department of Pathology, Xijing Hospital and School of Basic Medicine, Fourth Military Medical University, 710032, Xi'an, Shaanxi, China.
Yuan Y; State Key Laboratory of Cancer Biology, Department of Pathology, Xijing Hospital and School of Basic Medicine, Fourth Military Medical University, 710032, Xi'an, Shaanxi, China.
Xiao L; State Key Laboratory of Cancer Biology, Department of Pathology, Xijing Hospital and School of Basic Medicine, Fourth Military Medical University, 710032, Xi'an, Shaanxi, China.
Zhang J; Institude of Cancer, Xinqiao Hospital, Army Medical University, 400037, Chongqing, China.
Sun C; Department of Neurology, Tangdu Hospital, Fourth Military Medical University, 710038, Xi'an, Shaanxi, China.
Yang H; State Key Laboratory of Cancer Biology, Department of Pathology, Xijing Hospital and School of Basic Medicine, Fourth Military Medical University, 710032, Xi'an, Shaanxi, China.
Qin J; State Key Laboratory of Cancer Biology, Department of Pathology, Xijing Hospital and School of Basic Medicine, Fourth Military Medical University, 710032, Xi'an, Shaanxi, China.
Li J; State Key Laboratory of Cancer Biology, Department of Pathology, Xijing Hospital and School of Basic Medicine, Fourth Military Medical University, 710032, Xi'an, Shaanxi, China.
Zhang F; State Key Laboratory of Cancer Biology, Department of Pathology, Xijing Hospital and School of Basic Medicine, Fourth Military Medical University, 710032, Xi'an, Shaanxi, China.
Zhang L; Department of Clinical Diagnosis, Tangdu Hospital, Fourth Military Medical University, 710038, Xi'an, Shaanxi, China. .
Ye J; State Key Laboratory of Cancer Biology, Department of Pathology, Xijing Hospital and School of Basic Medicine, Fourth Military Medical University, 710032, Xi'an, Shaanxi, China. .
Pokaż więcej
Źródło :
Oncogene [Oncogene] 2020 Oct; Vol. 39 (40), pp. 6340-6353. Date of Electronic Publication: 2020 Aug 27.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Brain/*pathology
Brain Neoplasms/*genetics
Glioma/*genetics
Hydroxycholesterols/*metabolism
Isocitrate Dehydrogenase/*genetics
Animals ; Astrocytes/metabolism ; Atorvastatin/therapeutic use ; Brain/cytology ; Brain Neoplasms/pathology ; Cell Line, Tumor ; Gene Knock-In Techniques ; Glioma/drug therapy ; Glioma/pathology ; Humans ; Hydroxymethylglutaryl CoA Reductases/metabolism ; Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use ; Isocitrate Dehydrogenase/metabolism ; Mice ; Mice, Transgenic ; Mutation ; Myelin Sheath/pathology ; Primary Cell Culture
Czasopismo naukowe
Tytuł :
Teenage mutant neutrophilic precursors: Leukemia cutis with IDH2 mutation on enasidenib therapy.
Autorzy :
Kallen ME; Department of Pathology, University of Maryland School of Medicine, Baltimore, MD, United States. Electronic address: .
Koka R; Department of Pathology, University of Maryland School of Medicine, Baltimore, MD, United States.
Singh Z; Department of Pathology, University of Maryland School of Medicine, Baltimore, MD, United States.
Sanchez-Petitto G; Department of Medicine, Division of Hematology / Oncology, University of Maryland School of Medicine, Baltimore, MD, United States.
Zaman QU; University of Pittsburgh Medical Center, Western Maryland, Cumberland, MD, United States.
Yared JA; Department of Medicine, Division of Hematology / Oncology, University of Maryland School of Medicine, Baltimore, MD, United States.
Duong VH; Department of Medicine, Division of Hematology / Oncology, University of Maryland School of Medicine, Baltimore, MD, United States.
Pokaż więcej
Źródło :
Leukemia research [Leuk Res] 2020 Sep; Vol. 96, pp. 106406. Date of Electronic Publication: 2020 Jun 25.
Typ publikacji :
Case Reports; Letter
MeSH Terms :
Mutation*
Aminopyridines/*adverse effects
Cellulitis/*pathology
Isocitrate Dehydrogenase/*genetics
Leukemia, Myeloid, Acute/*drug therapy
Neutrophils/*pathology
Skin Diseases/*pathology
Triazines/*adverse effects
Cellulitis/etiology ; Humans ; Isocitrate Dehydrogenase/antagonists & inhibitors ; Leukemia, Myeloid, Acute/genetics ; Leukemia, Myeloid, Acute/pathology ; Male ; Middle Aged ; Neutrophils/drug effects ; Prognosis ; Skin Diseases/etiology
Raport
Tytuł :
Commentary: The Correlation of Fluorescence of Protoporphyrinogen IX and Status of Isocitrate Dehydrogenase in Gliomas.
Autorzy :
Khatri D; Department of Neurosurgery, Lenox Hill Hospital, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, New York, New York.
Patel NV; Department of Neurosurgery, Lenox Hill Hospital, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, New York, New York.
Reichman N; Department of Neurosurgery, Lenox Hill Hospital, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, New York, New York.
Langer DJ; Department of Neurosurgery, Lenox Hill Hospital, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, New York, New York.
Boockvar JA; Department of Neurosurgery, Lenox Hill Hospital, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, New York, New York.
Pokaż więcej
Źródło :
Neurosurgery [Neurosurgery] 2020 Aug 01; Vol. 87 (2), pp. E121-E122.
Typ publikacji :
Journal Article; Comment
MeSH Terms :
Glioma*
Isocitrate Dehydrogenase*
Fluorescence ; Humans ; Protoporphyrins
Czasopismo naukowe
Tytuł :
Clinical pharmacokinetics and pharmacodynamics of ivosidenib in patients with advanced hematologic malignancies with an IDH1 mutation.
Autorzy :
Fan B; Agios Pharmaceuticals, Inc., Cambridge, MA, USA. .
Dai D; Agios Pharmaceuticals, Inc., Cambridge, MA, USA.
DiNardo CD; University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Stein E; Memorial Sloan Kettering Cancer Center, New York, NY, USA.
de Botton S; Institut Gustave Roussy, Villejuif, France.
Attar EC; Agios Pharmaceuticals, Inc., Cambridge, MA, USA.
Liu H; Agios Pharmaceuticals, Inc., Cambridge, MA, USA.
Liu G; Agios Pharmaceuticals, Inc., Cambridge, MA, USA.
Lemieux I; Agios Pharmaceuticals, Inc., Cambridge, MA, USA.
Agresta SV; Agios Pharmaceuticals, Inc., Cambridge, MA, USA.
Yang H; Agios Pharmaceuticals, Inc., Cambridge, MA, USA.
Pokaż więcej
Źródło :
Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2020 May; Vol. 85 (5), pp. 959-968. Date of Electronic Publication: 2020 Apr 15.
Typ publikacji :
Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms :
Hematologic Neoplasms*/drug therapy
Hematologic Neoplasms*/genetics
Hematologic Neoplasms*/pathology
Isocitrate Dehydrogenase*/antagonists & inhibitors
Isocitrate Dehydrogenase*/genetics
Pyridines*/administration & dosage
Pyridines*/adverse effects
Pyridines*/pharmacokinetics
Glycine/*analogs & derivatives
Aged ; Antineoplastic Agents/administration & dosage ; Antineoplastic Agents/adverse effects ; Antineoplastic Agents/pharmacokinetics ; Dose-Response Relationship, Drug ; Drug Administration Schedule ; Drug Monitoring/methods ; Female ; Glycine/administration & dosage ; Glycine/adverse effects ; Glycine/pharmacokinetics ; Humans ; Leukemia, Myeloid, Acute/drug therapy ; Leukemia, Myeloid, Acute/genetics ; Leukemia, Myeloid, Acute/pathology ; Male ; Maximum Tolerated Dose ; Mutation ; Neoplasm Staging ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Integrated pharmaco-proteogenomics defines two subgroups in isocitrate dehydrogenase wild-type glioblastoma with prognostic and therapeutic opportunities.
Autorzy :
Oh S; Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Korea.; Brain Korea 21 PLUS Project for Medical Science, Yonsei University College of Medicine, Seoul, Korea.
Yeom J; Center for Theragnosis, Korea Institute of Science and Technology, Seoul, Korea.; Division of Bio-Medical Science & Technology, KIST School, Korea University of Science and Technology, Seoul, Korea.; Convergence Medicine Research Center, Asan Institute for Life Sciences, Seoul, Korea.
Cho HJ; Institute for Refractory Cancer Research, Samsung Medical Center, Seoul, Korea.; Precision Medicine Research Institute, Samsung Medical Center, Seoul, Korea.
Kim JH; Graduate Program for Nanomedical Science, Yonsei University, Seoul, Korea.
Yoon SJ; Brain Korea 21 PLUS Project for Medical Science, Yonsei University College of Medicine, Seoul, Korea.; Department of Biochemistry and Molecular Biology, Yonsei University College of Medicine, Seoul, Korea.
Kim H; Brain Korea 21 PLUS Project for Medical Science, Yonsei University College of Medicine, Seoul, Korea.
Sa JK; Department of Biomedical Sciences, Korea University College of Medicine, Seoul, Korea.
Ju S; Center for Theragnosis, Korea Institute of Science and Technology, Seoul, Korea.; Department of Life Science and Research Institute for Natural Sciences, Hanyang University, Seoul, Korea.
Lee H; Brain Korea 21 PLUS Project for Medical Science, Yonsei University College of Medicine, Seoul, Korea.; Department of Systems Biology, College of Life Science and Biotechnology, Yonsei University, Seoul, Korea.
Oh MJ; Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Korea.
Lee W; Department of Computer Science, Hanyang University, Seoul, Korea.
Kwon Y; Center for Theragnosis, Korea Institute of Science and Technology, Seoul, Korea.; Department of Life Science and Research Institute for Natural Sciences, Hanyang University, Seoul, Korea.
Li H; Department of Computer Science, Hanyang University, Seoul, Korea.; School of Computer Science and Engineering, Soongsil University, Seoul, Korea.
Choi S; Department of Computer Science, Hanyang University, Seoul, Korea.
Han JH; Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Korea.; Department of Medical Science, Yonsei University Graduate School, Seoul, Korea.
Chang JH; Department of Neurosurgery, Brain Tumor Center, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
Choi E; Institute for Refractory Cancer Research, Samsung Medical Center, Seoul, Korea.; Department of Neurosurgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Kim J; Institute for Refractory Cancer Research, Samsung Medical Center, Seoul, Korea.; Precision Medicine Research Institute, Samsung Medical Center, Seoul, Korea.
Her NG; Institute for Refractory Cancer Research, Samsung Medical Center, Seoul, Korea.
Kim SH; Department of Pathology, Yonsei University College of Medicine, Seoul, Korea.
Kang SG; Department of Medical Science, Yonsei University Graduate School, Seoul, Korea.; Department of Neurosurgery, Brain Tumor Center, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
Paek E; Department of Computer Science, Hanyang University, Seoul, Korea. .
Nam DH; Institute for Refractory Cancer Research, Samsung Medical Center, Seoul, Korea. .; Department of Neurosurgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. .; Department of Health Sciences and Technology, SAIHST, Sungkyunkwan University, Seoul, Korea. .
Lee C; Center for Theragnosis, Korea Institute of Science and Technology, Seoul, Korea. .; Division of Bio-Medical Science & Technology, KIST School, Korea University of Science and Technology, Seoul, Korea. .; Department of Converging Science and Technology, KHU-KIST, Kyung Hee University, Seoul, Korea. .
Kim HS; Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Korea. .; Brain Korea 21 PLUS Project for Medical Science, Yonsei University College of Medicine, Seoul, Korea. .
Pokaż więcej
Źródło :
Nature communications [Nat Commun] 2020 Jul 03; Vol. 11 (1), pp. 3288. Date of Electronic Publication: 2020 Jul 03.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Biomarkers, Tumor/*metabolism
Brain Neoplasms/*metabolism
Glioblastoma/*metabolism
Isocitrate Dehydrogenase/*genetics
Proteogenomics/*methods
Proteomics/*methods
Benzamides/pharmacology ; Biomarkers, Tumor/genetics ; Brain Neoplasms/genetics ; Brain Neoplasms/therapy ; Cell Line, Tumor ; Cell Survival/drug effects ; Cell Survival/genetics ; Glioblastoma/genetics ; Glioblastoma/therapy ; Humans ; Isocitrate Dehydrogenase/classification ; Isocitrate Dehydrogenase/metabolism ; Kaplan-Meier Estimate ; Mechanistic Target of Rapamycin Complex 1/antagonists & inhibitors ; Mechanistic Target of Rapamycin Complex 1/metabolism ; Mechanistic Target of Rapamycin Complex 2/antagonists & inhibitors ; Mechanistic Target of Rapamycin Complex 2/metabolism ; Morpholines/pharmacology ; Mutation ; Prognosis ; Protein Kinase Inhibitors/pharmacology ; Pyrimidines/pharmacology
Czasopismo naukowe
Tytuł :
Molecular modeling studies to discover novel mIDH2 inhibitors with high selectivity for the primary and secondary mutants.
Autorzy :
Yao K; State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases, Center of Drug Discovery, China Pharmaceutical University, Nanjing, 210009, China.
Liu H; State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases, Center of Drug Discovery, China Pharmaceutical University, Nanjing, 210009, China.
Liu P; State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases, Center of Drug Discovery, China Pharmaceutical University, Nanjing, 210009, China.
Liu W; State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases, Center of Drug Discovery, China Pharmaceutical University, Nanjing, 210009, China.
Yang J; Laboratory of Cellular and Molecular Biology, Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing, 210046, China; Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, 210046, China.
Wei Q; Laboratory of Cellular and Molecular Biology, Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing, 210046, China; Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, 210046, China.
Cao P; Laboratory of Cellular and Molecular Biology, Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing, 210046, China; Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, 210046, China. Electronic address: .
Lai Y; State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases, Center of Drug Discovery, China Pharmaceutical University, Nanjing, 210009, China. Electronic address: .
Pokaż więcej
Źródło :
Computational biology and chemistry [Comput Biol Chem] 2020 Jun; Vol. 86, pp. 107261. Date of Electronic Publication: 2020 Apr 15.
Typ publikacji :
Journal Article
MeSH Terms :
Enzyme Inhibitors/*chemistry
Isocitrate Dehydrogenase/*antagonists & inhibitors
Animals ; Cell Membrane Permeability ; Dogs ; Drug Discovery ; Enzyme Inhibitors/pharmacology ; Humans ; Intestinal Absorption ; Isocitrate Dehydrogenase/chemistry ; Isocitrate Dehydrogenase/genetics ; Ligands ; Madin Darby Canine Kidney Cells ; Molecular Docking Simulation ; Molecular Dynamics Simulation ; Mutation ; Protein Binding
Czasopismo naukowe
Tytuł :
Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.
Autorzy :
Abou-Alfa GK; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medicine, Weill Medical College at Cornell University, New York, NY, USA.
Macarulla T; Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
Javle MM; Department of Gastrointestinal Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA.
Kelley RK; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.
Lubner SJ; Department of Medicine, University of Wisconsin Carbone Cancer Center, Madison, WI, USA.
Adeva J; Department of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain.
Cleary JM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Catenacci DV; Department of Medicine, University of Chicago Medical Center, Chicago, IL, USA.
Borad MJ; Department of Hematology-Oncology, Mayo Clinic Cancer Center, Phoenix, AZ, USA.
Bridgewater J; Department of Medical Oncology, UCL Cancer Institute, London, UK.
Harris WP; Department of Medicine, University of Washington, Seattle, WA, USA.
Murphy AG; Department of Oncology-Gastrointestinal Cancer, Johns Hopkins University, Baltimore, MD, USA.
Oh DY; Department of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea.
Whisenant J; Medical Oncology and Hematology, Utah Cancer Specialists, Salt Lake City, UT, USA.
Lowery MA; Trinity St James Cancer Institute, Trinity College Dublin, Dublin, Ireland.
Goyal L; Department of Medicine, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
Shroff RT; Department of Medicine, University of Arizona Cancer Center, Tucson, AZ, USA.
El-Khoueiry AB; Department of Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA, USA.
Fan B; Agios Pharmaceuticals, Cambridge, MA, USA.
Wu B; Agios Pharmaceuticals, Cambridge, MA, USA.
Chamberlain CX; Agios Pharmaceuticals, Cambridge, MA, USA.
Jiang L; Agios Pharmaceuticals, Cambridge, MA, USA.
Gliser C; Agios Pharmaceuticals, Cambridge, MA, USA.
Pandya SS; Agios Pharmaceuticals, Cambridge, MA, USA.
Valle JW; Division of Cancer Sciences, University of Manchester, Manchester, UK; Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK.
Zhu AX; Department of Medicine, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA; Jiahui International Cancer Center, Jiahui Health, Shanghai, China. Electronic address: .
Pokaż więcej
Źródło :
The Lancet. Oncology [Lancet Oncol] 2020 Jun; Vol. 21 (6), pp. 796-807. Date of Electronic Publication: 2020 May 13.
Typ publikacji :
Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Drug Resistance, Neoplasm*
Mutation*
Antineoplastic Agents/*administration & dosage
Bile Duct Neoplasms/*drug therapy
Cholangiocarcinoma/*drug therapy
Enzyme Inhibitors/*administration & dosage
Glycine/*analogs & derivatives
Isocitrate Dehydrogenase/*antagonists & inhibitors
Pyridines/*administration & dosage
Adult ; Aged ; Aged, 80 and over ; Antineoplastic Agents/adverse effects ; Bile Duct Neoplasms/enzymology ; Bile Duct Neoplasms/genetics ; Bile Duct Neoplasms/pathology ; Cholangiocarcinoma/enzymology ; Cholangiocarcinoma/genetics ; Cholangiocarcinoma/pathology ; Disease Progression ; Double-Blind Method ; Enzyme Inhibitors/adverse effects ; Europe ; Female ; Glycine/administration & dosage ; Glycine/adverse effects ; Humans ; Isocitrate Dehydrogenase/genetics ; Isocitrate Dehydrogenase/metabolism ; Male ; Middle Aged ; Progression-Free Survival ; Pyridines/adverse effects ; Republic of Korea ; Time Factors ; United States
Czasopismo naukowe
Tytuł :
Vascular habitat analysis based on dynamic susceptibility contrast perfusion MRI predicts IDH mutation status and prognosis in high-grade gliomas.
Autorzy :
Wu H; Department of Radiology, Army Medical Center of PLA, Army Medical University, 10# Changjiangzhilu, Chongqing, 400042, People's Republic of China.; Chongqing Clinical Research Centre of Imaging and Nuclear Medicine, Chongqing, 400042, China.
Tong H; Department of Radiology, Army Medical Center of PLA, Army Medical University, 10# Changjiangzhilu, Chongqing, 400042, People's Republic of China.; Chongqing Clinical Research Centre of Imaging and Nuclear Medicine, Chongqing, 400042, China.
Du X; Department of Radiology, Army Medical Center of PLA, Army Medical University, 10# Changjiangzhilu, Chongqing, 400042, People's Republic of China.; Chongqing Clinical Research Centre of Imaging and Nuclear Medicine, Chongqing, 400042, China.
Guo H; Department of Radiology, Army Medical Center of PLA, Army Medical University, 10# Changjiangzhilu, Chongqing, 400042, People's Republic of China.; Chongqing Clinical Research Centre of Imaging and Nuclear Medicine, Chongqing, 400042, China.
Ma Q; Department of Pathology, Army Medical Center of PLA, Army Medical University, 10# Changjiangzhilu, Chongqing, 400042, People's Republic of China.
Zhang Y; Department of Radiology, Army Medical Center of PLA, Army Medical University, 10# Changjiangzhilu, Chongqing, 400042, People's Republic of China.; Chongqing Clinical Research Centre of Imaging and Nuclear Medicine, Chongqing, 400042, China.
Zhou X; MR Collaboration, Siemens Healthineers Ltd., Shanghai, China.
Liu H; Department of Radiology, Army Medical Center of PLA, Army Medical University, 10# Changjiangzhilu, Chongqing, 400042, People's Republic of China.; Chongqing Clinical Research Centre of Imaging and Nuclear Medicine, Chongqing, 400042, China.
Wang S; Department of Radiology, Army Medical Center of PLA, Army Medical University, 10# Changjiangzhilu, Chongqing, 400042, People's Republic of China.; Chongqing Clinical Research Centre of Imaging and Nuclear Medicine, Chongqing, 400042, China.
Fang J; Department of Radiology, Army Medical Center of PLA, Army Medical University, 10# Changjiangzhilu, Chongqing, 400042, People's Republic of China. .
Zhang W; Department of Radiology, Army Medical Center of PLA, Army Medical University, 10# Changjiangzhilu, Chongqing, 400042, People's Republic of China. .; Chongqing Clinical Research Centre of Imaging and Nuclear Medicine, Chongqing, 400042, China. .
Pokaż więcej
Źródło :
European radiology [Eur Radiol] 2020 Jun; Vol. 30 (6), pp. 3254-3265. Date of Electronic Publication: 2020 Feb 20.
Typ publikacji :
Journal Article
MeSH Terms :
Mutation*
Brain Neoplasms/*diagnosis
Cerebral Blood Volume/*physiology
DNA/*genetics
Glioblastoma/*genetics
Isocitrate Dehydrogenase/*genetics
Magnetic Resonance Imaging/*methods
Brain Neoplasms/genetics ; Brain Neoplasms/metabolism ; DNA Mutational Analysis ; Female ; Glioblastoma/diagnosis ; Glioblastoma/metabolism ; Humans ; Isocitrate Dehydrogenase/metabolism ; Male ; Middle Aged ; Prognosis
Czasopismo naukowe
Tytuł :
Advances in Noninvasive Neurodiagnostics.
Autorzy :
Urgun K; Department of Neurological Surgery, University of California, Irvine Medical Center, Orange, California, USA.
Ball BZ; Department of Neurological Surgery, University of California, Irvine Medical Center, Orange, California, USA.
Hsu FPK; Department of Neurological Surgery, University of California, Irvine Medical Center, Orange, California, USA. Electronic address: .
Pokaż więcej
Źródło :
World neurosurgery [World Neurosurg] 2020 Jul; Vol. 139, pp. 1-3. Date of Electronic Publication: 2020 Mar 17.
Typ publikacji :
Journal Article
MeSH Terms :
Glioma*
Isocitrate Dehydrogenase*
Humans
Czasopismo naukowe
Tytuł :
SIRT3 and GCN5L regulation of NADP+- and NADPH-driven reactions of mitochondrial isocitrate dehydrogenase IDH2.
Autorzy :
Smolková K; Laboratory of Mitochondrial Physiology, No.75, Institute of Physiology of the Czech Academy of Sciences (IPHYS CAS), Vídeňská 1083, 14220, Prague, Czech Republic. .
Špačková J; Laboratory of Mitochondrial Physiology, No.75, Institute of Physiology of the Czech Academy of Sciences (IPHYS CAS), Vídeňská 1083, 14220, Prague, Czech Republic.
Gotvaldová K; Laboratory of Mitochondrial Physiology, No.75, Institute of Physiology of the Czech Academy of Sciences (IPHYS CAS), Vídeňská 1083, 14220, Prague, Czech Republic.
Dvořák A; Laboratory of Mitochondrial Physiology, No.75, Institute of Physiology of the Czech Academy of Sciences (IPHYS CAS), Vídeňská 1083, 14220, Prague, Czech Republic.; Institute of Medical Biochemistry and Laboratory Diagnostics, 1st Faculty of Medicine, Charles University, Prague, Czech Republic.
Křenková A; Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences (IOCB CAS), Prague, Czech Republic.
Hubálek M; Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences (IOCB CAS), Prague, Czech Republic.
Holendová B; Laboratory of Mitochondrial Physiology, No.75, Institute of Physiology of the Czech Academy of Sciences (IPHYS CAS), Vídeňská 1083, 14220, Prague, Czech Republic.
Vítek L; Institute of Medical Biochemistry and Laboratory Diagnostics, 1st Faculty of Medicine, Charles University, Prague, Czech Republic.
Ježek P; Laboratory of Mitochondrial Physiology, No.75, Institute of Physiology of the Czech Academy of Sciences (IPHYS CAS), Vídeňská 1083, 14220, Prague, Czech Republic.
Pokaż więcej
Źródło :
Scientific reports [Sci Rep] 2020 May 26; Vol. 10 (1), pp. 8677. Date of Electronic Publication: 2020 May 26.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Glutarates/*metabolism
Isocitrate Dehydrogenase/*metabolism
Mitochondria/*metabolism
Nerve Tissue Proteins/*metabolism
Sirtuin 3/*metabolism
Acetylation ; Cell Line, Tumor ; Gene Silencing ; Humans ; Isocitrate Dehydrogenase/genetics ; Isocitrates/chemistry ; NADP/metabolism ; Oxidation-Reduction
Czasopismo naukowe
Tytuł :
Association between glioblastoma cell-derived vessels and poor prognosis of the patients.
Autorzy :
Mei X; Department of Neurosurgery/Neuro-oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060, P. R. China.; Department of Neurosurgery, Sun Yat-sen Memorial Hospital, Guangzhou, Guangdong, 510235, P. R. China.
Chen YS; Department of Neurosurgery/Neuro-oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060, P. R. China.
Zhang QP; Department of Neurosurgery, Huazhong University of Science and Technology Union Shenzhen Hospital, The 6th Affiliated Hospital of Shenzhen University Health Science Center (Shenzhen Nanshan People's Hospital), Shenzhen, Guangdong, 518052, P. R. China.
Chen FR; Department of Neurosurgery/Neuro-oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060, P. R. China.
Xi SY; Department of Neurosurgery/Neuro-oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060, P. R. China.
Long YK; Department of Molecular Diagnostics, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060, P. R. China.
Zhang J; Department of Neurosurgery/Neuro-oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060, P. R. China.
Cai HP; Department of Neurosurgery/Neuro-oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060, P. R. China.
Ke C; Department of Neurosurgery/Neuro-oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060, P. R. China.
Wang J; Department of Neurosurgery/Neuro-oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060, P. R. China.
Chen ZP; Department of Neurosurgery/Neuro-oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060, P. R. China.
Pokaż więcej
Źródło :
Cancer communications (London, England) [Cancer Commun (Lond)] 2020 May; Vol. 40 (5), pp. 211-221. Date of Electronic Publication: 2020 May 02.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Brain Neoplasms/*genetics
DNA Modification Methylases/*genetics
DNA Repair Enzymes/*genetics
Glioblastoma/*genetics
Isocitrate Dehydrogenase/*genetics
Neovascularization, Pathologic/*genetics
Tumor Suppressor Proteins/*genetics
Animals ; Brain Neoplasms/blood supply ; Brain Neoplasms/surgery ; Cell Line, Tumor ; DNA Methylation ; Female ; Glioblastoma/blood supply ; Glioblastoma/surgery ; Humans ; Isocitrate Dehydrogenase/metabolism ; Kaplan-Meier Estimate ; Male ; Mice, Nude ; Middle Aged ; Mutation ; Neovascularization, Pathologic/metabolism ; Prognosis ; Xenograft Model Antitumor Assays/methods
Czasopismo naukowe
Tytuł :
Analysis of amino acid residues involved in the thermal properties of isocitrate dehydrogenases from a psychrophilic bacterium, Colwellia maris, and a psychrotrophic bacterium, Pseudomonas psychrophila.
Autorzy :
Nagai S; Biosystems Science Course, Graduate School of Life Science, Hokkaido University, Kita 10-jo Nishi 8-chome, Kita-ku, Sapporo 060-0810, Japan.
Takada Y; Department of Biological Sciences, Faculty of Science, Hokkaido University, Kita 10-jo Nishi 8-chome, Kita-ku, Sapporo 060-0810, Japan. Electronic address: .
Pokaż więcej
Źródło :
Journal of bioscience and bioengineering [J Biosci Bioeng] 2020 Mar; Vol. 129 (3), pp. 284-290. Date of Electronic Publication: 2019 Oct 13.
Typ publikacji :
Journal Article
MeSH Terms :
Alteromonadaceae/*enzymology
Isocitrate Dehydrogenase/*metabolism
Pseudomonas/*enzymology
Alteromonadaceae/genetics ; Amino Acid Sequence ; Amino Acids/analysis ; Enzyme Stability ; Isocitrate Dehydrogenase/chemistry ; Isocitrate Dehydrogenase/genetics ; Kinetics ; Mutagenesis, Site-Directed ; Pseudomonas/genetics ; Sequence Analysis, Protein ; Temperature
SCR Organism :
Colwellia maris; Pseudomonas psychrophila
Czasopismo naukowe
Tytuł :
Interaction between IDH1 WT and calmodulin and its implications for glioblastoma cell growth and migration.
Autorzy :
Kang S; Natural Product Research Institute, College of Pharmacy, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul, 08826, South Korea. Electronic address: .
Kwon HN; Natural Product Research Institute, College of Pharmacy, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul, 08826, South Korea; Stem Cells and Metabolism Research Program, Faculty of Medicine / Helsinki Institute of Life Science, University of Helsinki, Finland.
Kang S; Natural Product Research Institute, College of Pharmacy, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul, 08826, South Korea; Department of Biochemistry and Molecular Genetics, College of Medicine, University of Illinois at Chicago, Chicago, IL, 60607, USA.
Park S; Natural Product Research Institute, College of Pharmacy, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul, 08826, South Korea. Electronic address: .
Pokaż więcej
Źródło :
Biochemical and biophysical research communications [Biochem Biophys Res Commun] 2020 Mar 26; Vol. 524 (1), pp. 224-230. Date of Electronic Publication: 2020 Jan 23.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Cell Movement*/drug effects
Brain Neoplasms/*metabolism
Brain Neoplasms/*pathology
Calmodulin/*metabolism
Glioblastoma/*metabolism
Glioblastoma/*pathology
Isocitrate Dehydrogenase/*metabolism
Amino Acid Sequence ; Binding Sites ; Cell Line, Tumor ; Cell Proliferation/drug effects ; Humans ; Isocitrate Dehydrogenase/chemistry ; Models, Molecular ; Protein Binding/drug effects ; Trifluoperazine/pharmacology
Czasopismo naukowe
Tytuł :
Alternative lengthening of telomeres is the major telomere maintenance mechanism in astrocytoma with isocitrate dehydrogenase 1 mutation.
Autorzy :
Ferreira MSV; Department of Haematology, Oncology, Medical Faculty, RWTH Aachen, Pauwelsstrasse 30, 52074, Aachen, Germany.
Sørensen MD; Department of Pathology, University Hospital Odense, Sdr. Boulevard 29, 5000, Odense, Denmark.; Department of Clinical Research, University of Southern Denmark, Sdr. Boulevard 29, 5000, Odense, Denmark.
Pusch S; Department of Neuropathology, University of Heidelberg, Heidelberg, Germany.; Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), Heidelberg, Germany.; German Cancer Consortium (DKTK), Heidelberg, Germany.
Beier D; Department of Clinical Research, University of Southern Denmark, Sdr. Boulevard 29, 5000, Odense, Denmark.; Department of Neurology, University Hospital Odense, Sdr. Boulevard 29, 5000, Odense, Denmark.
Bouillon AS; Department of Haematology, Oncology, Medical Faculty, RWTH Aachen, Pauwelsstrasse 30, 52074, Aachen, Germany.
Kristensen BW; Department of Pathology, University Hospital Odense, Sdr. Boulevard 29, 5000, Odense, Denmark.; Department of Clinical Research, University of Southern Denmark, Sdr. Boulevard 29, 5000, Odense, Denmark.
Brümmendorf TH; Department of Haematology, Oncology, Medical Faculty, RWTH Aachen, Pauwelsstrasse 30, 52074, Aachen, Germany.
Beier CP; Department of Clinical Research, University of Southern Denmark, Sdr. Boulevard 29, 5000, Odense, Denmark.; Department of Neurology, University Hospital Odense, Sdr. Boulevard 29, 5000, Odense, Denmark.
Beier F; Department of Haematology, Oncology, Medical Faculty, RWTH Aachen, Pauwelsstrasse 30, 52074, Aachen, Germany. .
Pokaż więcej
Źródło :
Journal of neuro-oncology [J Neurooncol] 2020 Mar; Vol. 147 (1), pp. 1-14. Date of Electronic Publication: 2020 Jan 20.
Typ publikacji :
Journal Article
MeSH Terms :
Astrocytoma/*genetics
Brain Neoplasms/*genetics
Isocitrate Dehydrogenase/*genetics
Telomerase/*genetics
Telomere Homeostasis/*genetics
X-linked Nuclear Protein/*genetics
Adolescent ; Adult ; Aged ; Child ; Child, Preschool ; Female ; Humans ; Isocitrate Dehydrogenase/metabolism ; Male ; Middle Aged ; Mutation ; Single-Cell Analysis ; Tumor Cells, Cultured ; Young Adult
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies